RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Beijing’s Sinotau Pharma signed a non-binding MOU with Navidea Biopharma to transfer rights for Navidea’s beta-amyloid imaging agent to Cerveau Technologies. Cerveau is a Boston joint venture owned by Sinotau and Canada’s Enigma Biomedical. Currently, Sinotau is suing Navidea. It charges Navidea did not transfer the global rights for the beta-amyloid imaging agent, NAV4694, to Sinotau as previously agreed. In 2014, Navidea in-licensed rights to NAV4694 from AstraZeneca, but later decided to emphasize other projects.
Source: China Biotoday
